Know Cancer

forgot password

A Phase II Trial of Perillyl Alcohol (NSC 641066) Administered Daily In Patients With Metastatic Androgen Independent Prostate Cancer

Phase 2
Not Enrolling
Prostate Cancer

Thank you

Trial Information

A Phase II Trial of Perillyl Alcohol (NSC 641066) Administered Daily In Patients With Metastatic Androgen Independent Prostate Cancer

OBJECTIVES: I. Evaluate the clinical effectiveness of oral perillyl alcohol given to
patients with androgen independent metastatic prostate cancer. II. Assess the toxicity of
this treatment in these patients.

OUTLINE: Patients receive oral perillyl alcohol 4 times a day for 4 weeks. Patients continue
treatment in the absence of severe toxicity and disease progression. Patients are followed
every 3 months for survival after disease progression.

PROJECTED ACCRUAL: This study will accrue 20-40 patients in approximately 2 years.

Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically confirmed progressive metastatic or progressive
regional nodal adenocarcinoma of the prostate Regression of tumor following hormone
therapy If on antiandrogen therapy, must fail to respond to withdrawal or have progressive
disease following withdrawal of antiandrogen No CNS disease

PATIENT CHARACTERISTICS: Age: Not specified Performance status: WCCC 0-2 Life expectancy:
At least 3 months Hematopoietic: WBC at least 3000/mm3 Absolute neutrophil count at least
1200/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 8 g/dL Hepatic: Bilirubin
no greater than 1.5 mg/dL SGOT no greater than 2.5 times normal Renal: Creatinine no
greater than 1.5 times upper limit of normal Other: At least 5 years since prior
malignancy other than: Inactive nonmelanoma skin cancer Adequately treated stage I or II
cancer in complete remission No other serious illness No spinal cord compression symptoms

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Prior chemotherapy
required Endocrine therapy: Failed one secondary hormonal manipulation for metastatic
disease Concurrent testicular androgen suppression (LHRH) allowed No concurrent hormonal
therapy other than LHRH agonist At least 4 weeks since antiandrogen treatment in order to
evaluate for response withdrawal Radiotherapy: At least 4 weeks since prior radiation
therapy No prior strontium therapy Surgery: No prior orchiectomy Other: No concurrent
cholesterol lowering agents No concurrent supplemental vitamins No concurrent antioxidants

Type of Study:


Study Design:

Primary Purpose: Treatment

Principal Investigator

George Wilding, MD

Investigator Role:

Study Chair

Investigator Affiliation:

University of Wisconsin, Madison


United States: Federal Government

Study ID:




Start Date:

February 1998

Completion Date:

Related Keywords:

  • Prostate Cancer
  • recurrent prostate cancer
  • Prostatic Neoplasms



University of Wisconsin Comprehensive Cancer Center Madison, Wisconsin  53792
Gundersen Lutheran Medical Center La Crosse, Wisconsin  54601
Leonard C. Ferguson Cancer Center Freeport, Illinois  61032
Green Bay Oncology, Ltd. Green Bay, Wisconsin  54307-3453
Mercy Health System Janesville, Wisconsin  53545
Meriter Hospital Madison, Wisconsin  53715
Sinai Samaritan Medical Center - Milwaukee Milwaukee, Wisconsin  53201-0342
North Central Oncology Associates, S.C. Wausau, Wisconsin  54401